Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is an angiotensin II receptor antagonist with actions similar to those of losartan. It is indicated in the treatment of hypertension. Oral administration once a day.
At latest update, relevant published data on excretion into breast milk were not found.
Its pharmacokinetic data (very large volume of distribution, moderately high molecular weight and high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.
It is one of the sartanes (ARBs) with the longest half-life and oral bioavailability (Tamargo 2006), making it one of the least indicated during breastfeeding.
Reportedly, a newborn infant appeared with transient renal failure (kidney malfunction) whose mother had taken Telmisartan during pregnancy. (Pietrement 2003)
Until more data on this medication is available safer alternative drugs are preferred (Malachias 2016, Rowe 2013), especially in premature babies or during the neonatal period.